{"name":"Arog Pharmaceuticals, Inc.","slug":"arog-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Duanorubicin","genericName":"Duanorubicin","slug":"duanorubicin","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"Duanorubicin","genericName":"Duanorubicin","slug":"duanorubicin","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxNQmVQMTFxeVVDOGdvN29DUW15VnRVTHgxR1VMVXgyTTJ1TFl3V05HTVJWY3VCWGFXZXlYMnUzMThYRkFic1pFWWUzWFRteTRZdFVxNkk2RGpxQXd0NGNKaWg3ZTUyR3JQTVpHbHBlZGZ3SHc0ZGU0U1l3TmtoN3laM2Y3NXNkVUxqWFhRV0xRd2pWLUVSNFJFQ05oZjBIeEhCSUFhVTdQY3R6bEQzTksyNDV4LWpvRUZoU2M2bmZHMmp0dDliRHJvMU9QWEJ6b1BndWJxb3NvWWRxWjA0cXpia012dDlyR25POXZid0JISC1uU0VKX2c?oc=5","date":"2026-04-01","type":"trial","source":"Barchart.com","summary":"Glioma Clinical Trial Pipeline Appears Robust With 180+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com","headline":"Glioma Clinical Trial Pipeline Appears Robust With 180+ Key Pharma Companies Actively Working in the Domain | DelveInsig","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxNYmVyVlB4UG1ZUXhpb2dDRVdwQnp4UjZ4WEc1RVBnTzQ1WktIZmVFYU5xcE1oR1NHQi1DbXU0dE50dnUxY3hSbTVzVEdDRHljdFZMdVJlLXNDY3VhWXgzVjczNUx0VFM1ZHJCSnM0Vm5wYVZaRG5zRExIQm9EZjBGSHhnd2NkV0d3OEF5UzlEZFRpZzNGQlVzWjctVzYtZWhGa0dsNVVTcUFJUUZTdTY5aUNTUlhDSXZPYTV2WDUyM2xtOHlCbF9VeWdvRmgzSGtxbkdZamZzaFkxYU1nekFhd1BpX2ZHRkctOWpjTFhHWkd2TVRzSkR1cWRvU2ZEYnVuMmtxNXV3?oc=5","date":"2026-03-30","type":"trial","source":"Barchart.com","summary":"Gastrointestinal Stromal Tumors Clinical Trial Pipeline Expands as 25+ Companies Driving Innovation in the Therapeutics | DelveInsight - Barchart.com","headline":"Gastrointestinal Stromal Tumors Clinical Trial Pipeline Expands as 25+ Companies Driving Innovation in the Therapeutics ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPdnhyNTBfbXVDNlFQTnJYUDZsdGxtRDVIVjFDT0EyQ0FmUEFQQ0hXT0RGc3Q1dDl0N3cwNDFZVXljY3lLVERfNV9jOTNBa2dWeVFfSTROeUFObi1uNXJpbTlVZ1NtMklWXzYzUV9PTmhld09CaUlYalhHQzRaX3hXUTBZNkpTekJfUFV5emFOVDBoT1ZEc01JZkY5ZFlTcDZ1cFJYNjNSVFB2NGdXODJpWg?oc=5","date":"2025-09-04","type":"deal","source":"Pharmaceutical Technology","summary":"Novartis adds again to siRNA pipeline with second deal in a day - Pharmaceutical Technology","headline":"Novartis adds again to siRNA pipeline with second deal in a day","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNMjhabXRyS3cybG42MXdOTkNXd1J4QXVYRGZKMkFjR3RUUUh2YnhUNzZYV24xWmkzZXI1ZjFCUzRFaUpmZFVTWHBMUHhlQ0ZNZVI2cXhzUmFtWU9idnZiMHI1NzY5WnNZX0VOaFZGVEtibm1jcDJFdkFZLVE2QURsSkc0M04waFVGT3FWSFVqS3lIZHc?oc=5","date":"2025-09-03","type":"deal","source":"BioPharma Dive","summary":"Novartis licenses RNA drugs in deal with China-based Argo - BioPharma Dive","headline":"Novartis licenses RNA drugs in deal with China-based Argo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxNUmU3OUctRkVvYWdEbVROYVBDbklxYkZScVd2QzdIcU5iUzZ4b1NwZHcySzhqa0MxU0FrTmNWb3dFcnNUSlRjTXp4WVRyMEU3N2QtamxsaUpKUDloSGpabDlMd3RGM2JvYVpVMWhpa2Q5UnNsQm5lT2dLeDUxN2JPeU03YW9xQ05pS1BhLURFWEpiM2tDcXBxa2JtTHlRZjB5SjlDTWJ6b2c3b0prejF5WmJnZEh4LXZRN3lfVlhxZmIyNURrRmdBMnhSM2pvWWdrQ0I0Y25Cd3JCR0J5X2ZXMG44RDZ1bFU?oc=5","date":"2025-09-03","type":"deal","source":"Reuters","summary":"Novartis signs up to $5.2 billion licensing deal with China's biotech Argo for heart drugs - Reuters","headline":"Novartis signs up to $5.2 billion licensing deal with China's biotech Argo for heart drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxNWDJjOFVpTlF6aFAtdzJaQnhleEptanI5dm1jZ2U3NkxpUVVMcjdrb0ZQXzRiV3BidlJXSS1QZVQzVEN1Njk1YU1lTGplWmU1RC1EeENhVDJET2FDSVFZNTFiWV9NeFo3YTAyQTRXV3JvbHNTY1EzTzV0Y1FyRFoydHh2RC10Tm9KdVZTNU9SbWM5MXpEdzJ2cG9zd1BMZjJ1VGpNeS0tWHJWOGpXelRialV5cmhydTFicXNoWmxLSTh2b1ltWVJGTm1OaXE3YVF6dksxeHNvbGNtalhLXzFidFVGZ2MwSkJF?oc=5","date":"2025-04-08","type":"pipeline","source":"prnewswire.com","summary":"TIBSOVO's Continued Success Solidifies Its Position as a Leader in IDH1 Mutant Space | DelveInsight - prnewswire.com","headline":"TIBSOVO's Continued Success Solidifies Its Position as a Leader in IDH1 Mutant Space | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTFBOc284aHEzZGJDSmJJYko3aG5WbXRmV0lmTkUtOWU1WlBsZnF5ZVpJVjRxRjI2N0FqTnRobFZISE1GbDh0ZXNZMTlqSFNDSWZJY0Fjd2hNNXR5SUlhZnFQMmFrV1Q3MFVqUVBFYnBUWEhBZ2pMV3ppTUdR?oc=5","date":"2024-11-25","type":"trial","source":"Wiley","summary":"Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia - Wiley","headline":"Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE01WFhab1Q1UlJISXd3akJKU2hqczJQSTVsNHBQMmtQWVpNSkQ3M3hybXFKa0UzSDBlbVJ5Vl84T0k3dVZISkloM2l2T09Da18zNW9xSHY5ZVlaZUktNE5vRV9kdWU2Mmc?oc=5","date":"2024-04-08","type":"pipeline","source":"Built In","summary":"13 Biotech Companies In Dallas To Know - Built In","headline":"13 Biotech Companies In Dallas To Know","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxQZjRXaUxqcmJGcXU5MmxfMUpYZ3FURWtNTjNFQzB0dy1lR3dVTG1SSUs0ajdhYVRiUXVFeDAwOHJTS2lPYTVGWUhYNXhwMEhfSk0zY0pnajQ2TVJ2R3Zxb0hJZW1BTk1lVGVUNnd0RG94dDBPVGM0N010TDhRRVVWYWxueFUwQnh1YlkxXzRqSDB5UldCUWM1WXNhVVd5MGVJZkNaZkpxQWQ1UHpzX0dLY3hGMjNpb0Z2T0RXSDB4eFVxdlNnZmZjUnZpZlRRMGtUSG12anRGSmJOTGxoQ1FIQkdLZDdKaHNnWDJTaTFtaU1EWjVWbWc?oc=5","date":"2023-03-31","type":"trial","source":"Digital Journal","summary":"Acute Myeloid Leukemia Market is anticipated to surpass US$ 4.31 billion By 2030: Data analysis by experts Growth Plus Reports - Digital Journal","headline":"Acute Myeloid Leukemia Market is anticipated to surpass US$ 4.31 billion By 2030: Data analysis by experts Growth Plus R","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTFBrNFZjZHU4QmhlVmhybU9iQlA0UldaR3c0Qk1QSnJFaXMyTTkxMWlEMDZWYlRGdmpxTElFYW5BZVE2Yl9WQmhwdU5UMmVuUnFIbmZTUnNxV2ZaaGdZMFhoVHVSZHltakZm?oc=5","date":"2023-01-23","type":"pipeline","source":"Straits Research","summary":"FLT3 Inhibitors Market Size, Top Share, Report to 2033 - Straits Research","headline":"FLT3 Inhibitors Market Size, Top Share, Report to 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQQ0JxV0F2cWoyekFYd0dPV2ZjZjZBX0NQeDA4OFJRM1RXWmJlUWkxNUNEb3NtbnZtRDI1OU5QSjYtcG1CUUs4OVJ0MG9wYURuWlBaSW5saF9WbVdwTmxULXQ3bWo5b3FacTJHRm5BNW5EbEkzcWdvQkxkaDlUQkltWTNyYTlVdw?oc=5","date":"2022-10-19","type":"pipeline","source":"Yahoo Finance","summary":"24+ Key Companies Actively Working in the Gastrointestinal Stromal Tumor Pipeline Segment | DelveInsight - Yahoo Finance","headline":"24+ Key Companies Actively Working in the Gastrointestinal Stromal Tumor Pipeline Segment | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPaWFXWE1mSTBJLVpMYzlZd2RLdHdmbjM2SktwSVlzeHhhdWxrQVZkaXRxWm1wN2FibTdoanVUWVhLNTNBQml6T3Y1dElWNVNmSmpvNHFXcmY2WUtkcGhlRXlEU3RERE5Ya18wYUhScThQYnVaTzVZdU10eDBHSlhGcw?oc=5","date":"2017-05-01","type":"regulatory","source":"BioPharma Dive","summary":"Novartis wins US approval of Rydapt for rare type of AML - BioPharma Dive","headline":"Novartis wins US approval of Rydapt for rare type of AML","sentiment":"positive"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":6,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}